Selank: Evidence Review of the Russian Anxiolytic Peptide

Selank is a synthetic heptapeptide — a seven-amino-acid molecule — developed in Russia as an anxiolytic and nootropic, usually given as an intranasal spray. It is a stabilized analogue of tuftsin, a natural immune-active peptide fragment, extended with a Pro–Gly–Pro tail to slow its breakdown^[4]. In Russia it has been studied for generalized anxiety and related disorders, and online it is sold grey-market as a “research peptide” nasal spray promoted for anxiety, focus, and mood. The honest evidence picture mirrors its sibling peptide Semax: the clinical research is almost entirely Russian, small, and has not been replicated in Western randomized controlled trials, and the compound is not approved by the FDA or any regulator outside Russia. Critically for this site — Selank is not a weight-loss peptide. No published study reports weight loss as an outcome, and we found no weight-loss trial in PubMed. This article reviews what Selank is, what the anxiety and cognitive evidence actually shows and where it falls short, the proposed mechanisms, its regulatory status, and the safety unknowns of an unapproved injectable/intranasal peptide. It is an evidence review — not a dosing or how-to-buy guide.

The honest summary

• It is a Russian anxiolytic/nootropic peptide, not a weight-loss drug. Selank (Thr–Lys–Pro–Arg–Pro–Gly–Pro) is a tuftsin analogue developed at the Institute of Molecular Genetics in Moscow and studied for anxiety and cognition^[4]. No published study reports weight loss as an outcome, and a PubMed search returns no Selank weight-loss trial.
• The clinical evidence is small and almost entirely Russian. The main human data are Russian-language reports in anxiety disorders — including a comparison with the benzodiazepine phenazepam^[1] and an “optimization of treatment” report^[2] — plus a small immunomodulatory study in patients with anxiety-asthenic disorders^[3]. These have not been replicated in independent Western randomized controlled trials.
• The mechanisms are plausible but mostly preclinical. Proposed actions include modulation of GABAergic and serotonergic systems and changes in BDNF (brain-derived neurotrophic factor), but much of this is from gene-expression and animal work^[5][6].
• It is not approved outside Russia. Selank has no FDA, EMA, or other Western approval. Outside Russia it circulates as an unregulated “research chemical” nasal spray, and a US pharmacology review groups it among non-approved GABA-acting agents of concern^[7].
• The safety profile is under-characterized. Russian reports describe it as well tolerated, but there are no large, long-term, independently audited safety trials, and the identity, purity, and dose of grey-market product are unverified.

What Selank actually is

Selank is a synthetic peptide built from a short natural sequence. Its core is tuftsin (Thr–Lys–Pro–Arg), a fragment of the immunoglobulin heavy chain with immune-modulating activity, to which researchers attached a Pro–Gly–Pro tripeptide tail. That tail is the clever part: free tuftsin is degraded almost immediately in the body, and the added residues make Selank far more stable so it can act long enough to have central nervous system effects^[4]. It was developed in Russia — at the Institute of Molecular Genetics together with the Zakusov Institute of Pharmacology — as a peptide anxiolytic intended to calm anxiety without the sedation, dependence, and withdrawal associated with benzodiazepines. Because peptides are poorly absorbed when swallowed, Selank is formulated as an intranasal solution. It belongs to the same family of Russian-developed “peptide neuromodulators” as Semax, and the two are frequently studied and marketed together.

The clinical evidence: small, Russian, and unreplicated

The human evidence for Selank in anxiety comes overwhelmingly from Russian clinical groups. The most cited work is a pair of reports led by Medvedev and colleagues: one comparing the anxiolytic effect and tolerability of Selank against the benzodiazepine phenazepam in patients with anxiety disorders^[1], and a companion report on optimizing the treatment of anxiety disorders with Selank^[2]. These describe Selank as producing an anxiolytic effect with a favorable tolerability profile — notably without the sedation and dependence concerns of benzodiazepines. A separate small study examined Selank’s immunomodulatory effects in patients with anxiety-asthenic disorders, reflecting its tuftsin-derived immune activity^[3].

The problem is not that these studies are negative — they are broadly positive — but that they are small, single-region, and have not been independently replicated. They are published largely in Russian-language journals, the trial designs and full data are not always accessible to Western reviewers, and no large multi-site randomized, double-blind, placebo-controlled trial of Selank has been published in the mainstream international literature. For a health claim, that matters: a treatment that looks promising in a handful of studies from a single research tradition has not cleared the bar of reproducible, independently verified evidence that Western regulators and clinicians require.

Proposed mechanisms: GABA, serotonin, and BDNF

Selank’s proposed mechanisms are biologically plausible and have some experimental support, but they are largely worked out in cells and animals rather than confirmed in humans. The leading hypotheses involve the brain’s inhibitory and mood systems. A gene-expression study found that Selank administration affects the expression of several genes involved in GABAergic neurotransmission^[5] — the same broad inhibitory system that benzodiazepines act on, which would fit an anti-anxiety effect. Other Russian work points to modulation of the serotonergic system and to changes in BDNF, a growth factor central to learning, memory, and resilience to stress: a rat study reported that Selank protected against ethanol-induced memory impairment while regulating BDNF content in the hippocampus and prefrontal cortex^[6]. A molecular review of the heptapeptide summarizes these proposed pathways alongside its tuftsin-derived immune activity and metabolic stability^[4].

None of this constitutes a proven, human-confirmed mechanism for clinical benefit. It is a coherent story — an inhibitory/serotonergic/neurotrophic peptide that could plausibly reduce anxiety and support cognition — but the gap between “changes gene expression in rats” or “modulates BDNF in a hippocampal model” and “reliably treats anxiety in people” is exactly the gap that large human trials exist to close, and those trials have not been done outside Russia.

Regulatory status: approved only in Russia, grey-market everywhere else

Selank is registered and used as a medicine in Russia, but it has no approval from the US FDA, the European EMA, or any other major regulator. That means everywhere outside Russia, any Selank you encounter is unapproved. Online it is sold as a “research peptide” nasal spray, typically labeled “for research use only — not for human consumption,” a disclaimer vendors use to ship it while sidestepping drug-marketing rules. A US clinical-pharmacology review of sedative-hypnotic and GABA-acting agents explicitly discusses Selank among substances of pharmacological and safety concern that fall outside the approved-drug system^[7]. The practical consequence is the familiar grey-market reality: no regulatory body has verified the identity, purity, sterility, or actual dose of what is in the bottle or vial.

Safety: described as well tolerated, but not well characterized

Russian clinical reports generally describe Selank as well tolerated, with one of its selling points being the absence of the sedation, dependence, and withdrawal seen with benzodiazepines such as phenazepam^[1]. The small immunomodulatory study in patients with anxiety-asthenic disorders likewise did not flag major safety problems^[3]. But “well tolerated in small short-term studies” is a long way from a fully characterized safety profile. There are no large, long-duration, independently audited safety trials; the populations studied are limited; and the long-term effects of chronic intranasal peptide use are not established. Combined with the grey-market sourcing problem, the honest statement is that Selank’s safety is under-characterized outside the Russian clinical setting — not that it is dangerous, and not that it is proven safe.

Selank is not a weight-loss peptide

It is worth stating plainly, because Selank sometimes appears on lists of “biohacker” peptides next to fat-loss compounds: Selank is not a weight-loss treatment, and there is no evidence it causes weight loss. Its development and study have been entirely in the domains of anxiety, mood, cognition, and immune modulation. We found no published study reporting weight loss as an outcome for Selank and no weight-loss trial of any kind in PubMed. Its proposed mechanisms — GABAergic, serotonergic, and BDNF-related^[5][6] — are about the nervous and immune systems, not appetite, satiety, or fat metabolism. Anyone marketing Selank for weight loss is making a claim with no supporting evidence. If weight loss is the goal, the evidence points to FDA-approved peptide medications with published human trials, not to an unapproved anxiolytic peptide.

For the broader context, see our hub review of peptides for weight loss, which separates FDA-approved peptide drugs from compounded and unapproved research peptides, our forthcoming A-to-Z peptide evidence guide, and the companion review of Semax, the sibling Russian nootropic peptide whose evidence story closely parallels Selank’s.

Bottom line

Selank is a real, Russian-developed anxiolytic peptide with a genuine but limited research record in anxiety and cognition, plus plausible GABAergic, serotonergic, and BDNF-related mechanisms that are still mostly preclinical^[4][5][6]. Its clinical evidence is small, almost entirely Russian, and unreplicated in Western randomized controlled trials^[1][2][3], and it is approved only in Russia — sold everywhere else as an unregulated research chemical of pharmacological concern^[7]. Its long-term safety is under-characterized. And it is not a weight-loss peptide: no study reports weight loss as an outcome, and there is no mechanistic reason to expect it. If your interest is anxiety, discuss evidence-based options with a clinician; if your interest is weight loss, look to treatments with real human trials instead.

This article is educational and is not medical advice. Every claim above is sourced to peer-reviewed literature indexed in PubMed or to the regulatory status of the compound, verified against the live PubMed database before publication. Citations 1 through 3 are Russian human clinical reports in anxiety; citation 7 is a US pharmacology review covering GABA-acting agents including Selank; citations 4 through 6 are mechanistic or preclinical studies. No citation reports weight loss as a Selank outcome because no such study exists. Discuss any treatment with a licensed prescriber.